Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Study Overview
=================
Brief Summary
-----------------
The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Official Title
-----------------
Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Conditions
-----------------
COVID, Corona Virus Infection

Intervention / Treatment
-----------------
* Biological: Specific anti-SARS-CoV-2 antibodies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Not previously diagnosed with COVID-19 except for convalescents Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea) Exclusion Criteria: Patients with fever or respiratory symptoms (cough, dyspnea) Refusal to give informed consent, or contraindication to venipuncture.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthcare workers (HCWs)<br> | Biological: Specific anti-SARS-CoV-2 antibodies<br>* A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).<br>|
| Healthy blood donors and healthy subjects in blood bank<br> | Biological: Specific anti-SARS-CoV-2 antibodies<br>* A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).<br>|
| Convalescents<br> | Biological: Specific anti-SARS-CoV-2 antibodies<br>* A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies |  | 3 Months |